When was Altimmune founded?

Altimmune was founded in 1997 and raised its 1st funding round 4 years after it was founded.

Where is Altimmune located?

Altimmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg,Maryland.

How many employees does Altimmune have?

As of Sep 30, 2026, the latest employee count at Altimmune is 88.

Is Altimmune a funded company?

Altimmune is a funded company, having raised a total of $58M across 22 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 01, 2001.

When was the latest funding round of Altimmune?

Altimmune's latest funding was a $***** Grant (prize money) round on Jun 29, 2020, with participation from 1 investor.

What is the annual revenue of Altimmune?

Annual revenue of Altimmune is less than $1M as on Dec 31, 2025

Where does Altimmune rank among its competitors?

Altimmune ranks 24th amongst 297 active competitors, of which 97 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Drug Farm, which secured $55M in Jul, 2026.

Who are the top competitors of Altimmune?

Altimmune's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Among them, Drug Farm secured the most recent funding round in July, 2026.

Altimmune - 2026 Company Profile, Team, Funding, Competitors & Financials

Altimmune is an acquired company based in Gaithersburg (United States), founded in 1997. It operates as a Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors. Altimmune has raised $58M in funding. The company has 297 active competitors, including 97 funded and 79 that have exited. Its top competitors include companies like Rhythm Pharmaceuticals, MannKind Corp and Adocia.

Company Details

Developer of vaccines for infectious diseases including influenza, hepatitis B, and solid tumors. The company has NasoVAX, an intranasally administered recombinant influenza vaccine, HepTcell, an immunotherapy for the chronic hepatitis B virus infection, ALT-801 for non-alcoholic steatohepatitis, T-COVID intranasal therapeutic for covid, and nasoshield for anthrax.

Website: altimmune.com
Registered Address: Gaithersburg,Maryland

Key Metrics

Founded Year

1997

Location

Gaithersburg, United States

Stage

Acquired

Total Funding

$58M in 22 rounds

Latest Funding Round

Grant (prize money), Jun 29, 2020, $*****

Investors

Gershon Capital & 16 more

Ranked

24^th among 297 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2025

Employee Count

88 as on Sep 30, 2026

Investment & Acquisitions

Immune Targeting Systems

Similar Companies

Adocia & 191 more

Exit Details

Acquired by PharmAthene (Jan 19, 2017)

View Altimmune's full profile

Altimmune is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Altimmune, Inc CIN: 1326190 , United States, Active	Apr 24, 2005	$0 - $1M (As on Dec 31, 2025)	-	-
Vaxin Inc. CIN: 631190888 , United States, Active	Dec 31, 1999	-	17 (As on Dec 31, 2016)	-
Pharmathene Inc. CIN: 202726770 , United States, Active		-	57 (As on Dec 31, 2024)	-

Altimmune got acquired by PharmAthene on Jan 19, 2017.

Click here to take a look at Altimmune's acquisition in detail

Altimmune has raised a total funding of $58M over 22 rounds. Its first funding round was on Jun 01, 2001. Its latest funding round was a Grant (prize money) round on Jun 29, 2020 for $*****. 1 investor participated in its latest round. Altimmune has 17 institutional investors.

Here is the list of recent funding rounds of Altimmune:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 29, 2020	5661609	Grant (prize money)	7539638	1284066	4645156	3869745
Aug 21, 2019	3607753	Grant (prize money)	8813484	9822799	6197902	Medical Countermeasures
Sep 24, 2018	6739898	Grant (prize money)	2571934	8023209	1340687	Medical Countermeasures

Access funding benchmarks and valuations. Sign up today!

View details of Altimmune's funding rounds and investors

Altimmune's employee count trend

Altimmune has 88 employees as of Sep 26. Here is Altimmune's employee count trend over the years:

Uncover Altimmune's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Altimmune include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Here is the list of Top 10 competitors of Altimmune, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
3rd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
4th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
5th	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Longitude Capital, BioBrit & 7 others	68/100
6th	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	HarbourVest Partners, Avoro Capital & 3 others	66/100
7th	Structure 2017, San Francisco (United States), Public	Developer of oral small molecule drugs for chronic diseases	$191M	BVF Partners, Janus Henderson Investors & 17 others	65/100
8th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
9th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	65/100
10th	Drug Farm 2015, Shanghai (China), Series D	Developer of a novel treatment for metabolic diseases	$138M	Shanghai Pudong Leading Area Investment Center, Zhejiang Private Enterprise United Investment ... & 13 others	64/100
24th	Altimmune 1997, Gaithersburg (United States), Acquired	Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors	$58M	Gershon Capital, Fidelis Capital & 15 others	62/100